中国现代医学杂志2004，Vol.14Issue(16)：13-15,20,4.
CD+4,CD+8及CD+4CD+8对于骨转移瘤治疗效果的监控作用
CD4+,CD8+ and CD4+/CD8+ in estimating therapeutic effects of bone metastases
房娜 1李勇 1杨志杰1
作者信息
- 1. 哈尔滨医科大学第一临床医学院,核医学科,黑龙江,哈尔滨,150001
- 折叠
摘要
Abstract
Objective: To judge the therapeutic effects of bone metastases by the percents of CD4+, CD8+,CD4+/CD8+ before and after the treatment of 89SrCl2 in the patients with bone metastases. Methods: 24 patients who were diagnosed by clinic were treated with 89SrCl2. The CD4+, CD8+ and CD4+/CD8+ were detected by flow cytometry before and after 89SrCl2 treatment, as well in 24 controls. At the 2nd, 4th and 6th month after the administration, the bone scan with 99mTc-MDP was performed for all the patients and the quantities of bone metastases lesions were recorded. Result: The percents of CD4+ and CD4+/CD8+ in the controls group were higher than those in the patients with bone metastases, and the CD8+ levels were lower (P＜0.05). After the treatment of 89SrCl2, the CD4+ and CD4+/CD8+ levels increased and the CD8+ level, the lesions decreased. These changes were the most obvious at the 4th month after the therapy. Conclusion: The CD4+, CD8+ and CD4+/CD8+ levels can sensitively reflect the therapeutic effects of 89SrCl2 and accurately estimate the conditions of bone metastases.关键词
骨转移瘤/T细胞亚群/89SrCl2/99mTc-MDPKey words
bone metastases/T lymphocyte subsets/89SrCl2/99mTc-MDP分类
医药卫生引用本文复制引用
房娜,李勇,杨志杰..CD+4,CD+8及CD+4CD+8对于骨转移瘤治疗效果的监控作用[J].中国现代医学杂志,2004,14(16):13-15,20,4.
